Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.47 |
| ▸ | SORD | Q00796 | 2/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954009 | 1.00 | TRPV1 (0.47) | TRPV1SORDOGAHRH3CNR2 | |
| SCHEMBL26711595 | 0.90 | TRPV1 (0.42) | TRPV1SORDOGAHRH3CNR2 | |
| SCHEMBL20361410 | 0.83 | TRPV1 (0.46) | TRPV1SORDOGAHRH3HRH4 | |
| SCHEMBL20361113 | 0.82 | HRH3 (0.49) | TRPV1SORDOGAHRH3 | |
| SCHEMBL7395300 | 0.81 | PTPN11 (0.48) | HRH3 | |
| SCHEMBL29519276 | 0.80 | TRPV1 (0.51) | TRPV1SORDOGAHRH3HRH4 | |
| SCHEMBL1427479 | 0.80 | TRPV1 (0.51) | TRPV1SORDOGAHRH3HRH4 | |
| SCHEMBL3949154 | 0.80 | TRPV1 (0.51) | TRPV1SORDOGAHRH3HRH4 | |
| SCHEMBL30954035 | 0.80 | HRH3 (0.66) | SORDOGAHRH3HRH4 | |
| SCHEMBL30693986 | 0.80 | HRH3 (0.43) | SORDHRH3CNR2PDE10AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514790-A1 | COMPOUNDS FOR INHIBITING KIF18A | Volastra Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024137984-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024137984-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2023212240-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | TRPV1 4790/4885SORD 3425/4885OGA 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.